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http:WHAT THIS PAPER ADDS
This study demonstrates that ExoSeal vascular closure of antegrade femoral access sites for peripheral in-
terventions is safe and effective in a real world situation. However, the results also show that it may be advisable
to prolong manual compression of the access site after VCD closure from 2 to 5 minutes in patients on anti-
platelet therapy, and especially after abciximab application to avoid residual bleeding.Objective: To retrospectively evaluate the efﬁcacy and time-to-hemostasis of antegrade femoral access closure
using the ExoSeal vascular closure device (VCD).
Design: Retrospective, single-center analysis.
Materials and methods: Between September 2010 and February 2013, 148 ExoSeal VCD closures (5e7F) of
antegrade femoral accesses were performed in 119 patients (70 males, mean age 71.6 years, range 40e97 years).
In all cases initial diagnostic angiography was performed via an 18G/3.8F retrograde femoral access, which was
left in place during intervention (in-house standard) and was used to obtain control angiography after successful
closure of the antegrade access to determine hemostasis. Technical device success was deﬁned as ExoSeal closure
without major VCD-related complications; procedural success as hemostasis within 5 minutes. Statistical analysis
was performed using a logistic regression model and correlation analyses.
Results: 145/148 (98.0%) ExoSeal closures were technically successful (5F: n ¼ 76; 6F: n ¼ 65; 7F: n ¼ 7).
Angiographic control showed closure after 2 minutes in 130/145 cases. In a further 14 cases hemostasis was
achieved after an additional 3 minutes MC, so that closure was successful within 5 minutes in 144/148 cases
(97.3%). No major complication occurred. One minor complication was recorded in a 6F access case. Pre-
interventional activated partial thromboplastin time (aPTT) was the only statistically signiﬁcant predictor of
necessary manual compression (MC) > 2 minutes (p ¼ .01), but with an odds-ratio of only 1.038. The INR showed
an odds-ratio of 2.455 for need for 5 minutes MC (NS). Signiﬁcant correlations were found between the need for
5 minutes MC and medication with acetylsalicylic acid (p ¼ .01), clopidogrel (p < .01), and abciximab (p < .001).
Conclusion: ExoSeal vascular closure of antegrade femoral punctures is safe and effective with a low complication
rate. Two minutes of MC are sufﬁcient to achieve hemostasis in the majority of cases. However, in patients on
antiplatelet therapy, especially after abciximab, the authors advocate prolonging MC to 5 minutes.
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Antegrade femoral accesses are an alternative to retrograde
crossover approaches for percutaneous transfemoral
revascularization. Antegrade puncture allows for easier
manipulation, better support, and improved pushability of
wires and catheters especially in cases of infrageniculartributed equally.
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//dx.doi.org/10.1016/j.ejvs.2014.08.006occlusive disease compared with crossover access. Howev-
er, antegrade femoral punctures are technically more chal-
lenging, especially in obese patients.1 Although manual
compression (MC) has long been regarded as the gold
standard for accomplishing hemostasis after transfemoral
vascular procedures, it is associated with patient discomfort
from groin pressure and immobilization.2 To overcome the
limitations of MC, vascular closure devices (VCDs) were ﬁrst
introduced in the 1990s3 and are also increasingly used for
closure of antegrade femoral access sites.4,5
The ExoSeal vascular closure device (Cordis Corporation,
Miami Lakes, FL, USA) is a bioabsorbable device available in
sizes from 5F to 7F. The safety and effectiveness of this
system has already been shown in several studies of
retrograde puncture closure with a low complication rate,
Table 1. Patient characteristics and indications for antegrade
transfemoral interventions.
Characteristic Value
Age, years 71.6 (40e97)
Male sex 70 (58.8%)
Anticoagulant therapy
Continuous ASS and heparin 67 (45.3%)
ASS, clopidogrel bisulfate, and heparin 40 (27.3%)
Heparin only 36 (24.3%)
ASS, heparin and abciximab 4 (2.7%)
Clopidogrel bisulfate and heparin 1 (0.7%)
Hemostatic parameters
Mean INR 1.11 (0.23 SD)
Mean pre-interventional aPTT 36.0 (14.0 SD)
Mean serum platelet count 287 (110 SD)
Clinical indications
PAD Fontaine grade IV 98 (66.2%)
PAD Fontaine grade III 19 (12.8%)
PAD Fontaine grade IIb 26 (17.6%)
Others 5 (3.4%)
ASS ¼ acetylsalicylic acid.
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to-hemostasis as well as time-to-ambulation.6e8
Initial results showed that the ExoSeal device can also be
used for antegrade vascular closure with a high technical
success rate.9,10 However, data on the use of the ExoSeal
VCD for antegrade femoral puncture closure are limited. In
the two studies available to date, efﬁcacy and safety were
mainly investigated using surrogate end points such as the
occurrence of minor or major complications (e.g. formation
of hematoma, pseudoaneurysm, or re-bleeding). Moreover,
data are only available for the 6F ExoSeal VCD.
The aim of the present study was to retrospectively eval-
uate the success rate and inﬂuencing factors on angio-
graphically determined time-to-hemostasis of antegrade
vascular closure using the ExoSeal VCD in sizes from 5F to 7F.
MATERIALS AND METHODS
Patient characteristics
Between September 2010 and February 2013, 148 angio-
graphic interventions were performed using antegrade
femoral access with ExoSeal closure of the puncture site
and additional angiographic control of hemostasis in 119
patients (70 males, 49 females, mean age 71.6 years, range
40e97 years). All interventions took place in daily routine
practice in an unselected patient group.
All patients underwent an interventional procedure after
antegrade puncture. There were no purely diagnostic ex-
aminations. Indications for intervention and patient char-
acteristics are summarized in Table 1.
This retrospective study was approved by the institu-
tional review board at the University of Bonn and informed
consent for the intervention was obtained from all patients.Procedure
Vascular closure was performed with 5e7F ExoSeal VCDs,
according to the manufacturer’s instructions. The ExoSealcan be inserted into a standard vascular sheath. After that,
both sheath and ExoSeal are pulled back until the vascular
wall is reached. A dual indicator system (bleed-back indi-
cator and intravascular nitinol-loop) ensures correct extra-
vascular plug deployment. Access size and the use of an
ExoSeal VCD were at the discretion of the interventional
radiologist. All interventionalists had previously performed
at least 50 closure procedures with the ExoSeal VCD. During
the study period the ExoSeal VCD was the only closure
device used for antegrade femoral access closure.
In all cases diagnostic overview DSA of the lower ex-
tremity was performed via a small retrograde femoral ac-
cess (18G/3.8F 10.8 cm long catheter introduced over a
20G/2.7F Needle [Arrow International, Reading, PA, USA]).
This technically easier retrograde approach is usually chosen
in patients without complete pre-interventional imaging of
the pelvic and leg arteries to allow for optimal planning of
the intervention itself. During the subsequent intervention
using antegrade femoral access, the short 18G/3.8F retro-
grade catheter was ﬂushed with heparinized saline and left
in place. No turn-around technique procedures were per-
formed. In general puncture of the femoral artery was
performed without ultrasound or roadmap guidance. Usu-
ally a wire was placed into the retrograde catheter to
facilitate antegrade puncture under ﬂuoroscopic guidance.
After completion of the endovascular procedure, ExoSeal
closure of the antegrade access was performed followed by
manual compression for 2 minutes. To determine successful
closure of the antegrade puncture site, control angiography
was obtained via the remaining 18G/3.8F retrograde access
after 2 minutes MC in all cases of successful plug-
deployment. In cases of unsuccessful hemostasis, manual
compression was performed for a further 3 minutes. If
subsequent digital subtraction angiography (DSA) showed
successful hemostasis, the retrograde access was removed
and closed with additional manual compression for 5
minutes.
All patients received a light compression bandage (rolled-
up gauze bandage at the puncture site with 10 cm wide
elastic bandages wrapped around the patient to apply local
pressure), and were mobilized after 6 hours’ bedrest.
In cases of device failure manual compression was
applied until hemostasis was achieved (at least 15 minutes)
followed by compression bandage and bed-rest for 12
hours.
Antegrade VCD closure was attempted in all cases. There
was no exclusion for obese patients, patients who had un-
dergone a challenging antegrade puncture of the common
femoral artery, or patients with stent material near to the
common femoral artery.
Patients received 5000 IU heparin at the beginning of the
procedure which was reinforced in complex interventions
(>1e1.5 hours) with an additional 1000 IU heparin per
hour, followed by intravenous heparin administration for
the next 24 hours (activated partial thromboplastin time
[aPTT] 60e80 seconds). Heparin effects were not reversed.
Phenprocoumon was substituted with heparin prior to
intervention.
Table 2. Procedure characteristics and results after antegrade vascular closure with the ExoSeal vascular closure device (VCD).
Procedure characteristics and results Size of VCD Total values
5 F 6 F 7 F
Total number of VCD used 76 (51.4) 65 (43.9) 7 (4.7) 148
Technical device success ratea 74 (97.4) 64 (98.5) 7 (100.0) 145 (98.0)
Device failed to deploy 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
No safe extravascular plug deployment 1 (1.32) 0 (0.0) 0 (0.0) 1 (0.7)
Puncture angle too steep 1 (1.32) 1 (1.5) 0 (0.0) 2 (1.35)
Procedural success ratea 74 (97.4) 63 (96.9) 7 (100.0) 144 (97.3)
Technical device failure 2 (2.6) 1 (1.5) 0 (0.0) 3 (2.0)
Hemostasis not achieved in 5 min 0 (0.0) 1 (1.5) 0 (0.0) 1 (0.7)
Additional compression bandage 76 (100.0) 65 (100.0) 7 (100.0) 148 (100.0)
Major complications 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Minor complications 0 (0.0) 1 (0.7) 0 (0.0) 1 (0.7)
Mild groin hematoma 3 cm 0 (0.0) 1 (0.7) 0 (0.0) 1 (0.7)
Groin hematoma 6 cm 0 (0.0) 0 (1.0) 0 (0.0) 0 (0.0)
Pseudoaneurysm 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Intravascular plug application 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Direct angiographic control of hemostasis 74 (97.4) 64 (98.5) 7 (100.0) 145 (98.0)
Hemostasis in 2 min 68 (91.9) 55 (85.9) 7 (100.0) 130 (89.7)
Hemostasis in 5 min 6 (8.1) 8 (12.5) 0 (0.0) 14 (9.7)
Hemostasis not achieved in 5 min 0 (0.0) 1 (1.6) 0 (0.0) 1 (0.7)
Data show the number of vascular closures with percentages in parentheses.
a Technical device success: successful ExoSeal closure without major VCD-related complications; Procedural success: successful ExoSeal
closure and manual compression of no longer than 5 minutes without major VCD-related vascular complications.
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evaluated pre- and immediately post-interventionally. All
patients were admitted overnight. The puncture sites were
examined hourly for 6 hours after the procedure and the
following day before discharge. Cases of device failure,
procedural difﬁculties, and evidence of vascular complica-
tions associated with the closure procedure were noted,
and appropriate therapy was given.Deﬁnitions
Technical device success was deﬁned as successful ExoSeal
closure without major vascular complications related to the
VCD.
Procedural success was deﬁned as successful plug-
deployment and manual compression of no longer than 5
minutes without major vascular complications attributed to
the closure procedure.
Major adverse events were deﬁned according to the
ECLIPSE trial: 1) need for vascular repair by surgical or
nonsurgical techniques; 2) bleeding requiring a blood
transfusion; 3) infection requiring antibiotics, extended
hospitalization, or both; 4) new onset ischemia of the
ipsilateral lower extremity; 5) need for surgical repair of
access-site-related nerve injury; 6) permanent access site-
related nerve injury.6
Minor postprocedural complications were deﬁned as: 1)
recurrent local bleeding requiring a hemostatic interven-
tion, or a 6 cm hematoma or; 2) development of pseu-
doaneurysm, arteriovenous ﬁstula, vascular laceration, or
retroperitoneal bleeding; 3) ipsilateral manifestations of
vascular insufﬁciency or embolization, including loss of
distal pulse, total arterial occlusion, or deep vein throm-
bosis; 4) infection; and 5) nerve injury.6Data analysis
The data were analyzed on an intention-to-treat basis.
Hemostasis-relevant patient history including patient age,
pre- and intra-interventional medication (heparin, ace-
tylsalicylic acid [ASS], clopidogrel bisulfate, abciximab),
laboratory ﬁndings (international normalized ratio [INR],
aPTT, platelet count), access size, procedure characteristics,
especially the time to angiographically conﬁrmed hemo-
stasis, as well as any complications were recorded. The data
are reported as mean and standard deviation for continuous
variables, and frequencies (in percentages) for categorical
variables.
All data from the patient’s ﬁrst ExoSeal closure procedure
(n ¼ 119 procedures), were then subjected to statistical
analysis. Repeated closures were excluded. Continuous
variables (patient age, platelet count, INR, and aPTT) were
analyzed using a logistic regression model for the proba-
bility of the need for 5 minutes manual compression to
achieve hemostasis. In the remaining discrete variables (sex,
access size, presence of hypertension, use of heparin, ASS,
clopidogrel, abciximab, or any combination of medication),
tests were done for interrelations between time-to-
hemostasis and these hemostasis-relevant parameters us-
ing a two-sided chi-square test or a Fisher’s Exact test for
small sample sizes. Results were considered to be statisti-
cally signiﬁcant if a p value <.05 was reached.RESULTS
A total of 148 ExoSeal VCDs (5F: n ¼ 76; 6F: n ¼ 65; 7F:
n ¼ 7) were deployed in 119 patients (see also Table 2).
19 patients received two interventions with the ExoSeal
vascular closure, two patients received three, and two pa-
tients received four interventions (mean time between
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second ExoSeal vascular closure was performed within 3
months.
The technical device success rate for antegrade closures
was 98.0% (145/148 ExoSeal deployments). In two cases
plug deployment was not possible because of a steep
puncture angle in obese patients, and in a third case secure
extravascular device deployment was not possible in a
heavily calciﬁed femoral artery; the vascular closure pro-
cedure was therefore aborted and the system removed in
toto, and manual compression applied.
The procedural success rate was 97.3% (144/148 plug
deployments). In three cases procedural success was not
achieved because of the above mentioned technical failure.
In one additional case hemostasis was not achieved in less
than 5 minutes. Successful closure was therefore performed
by prolonged manual compression for 15 minutes followed
by compression bandaging of the puncture site.
In 130/145 technically successful procedures, angiog-
raphy showed prompt closure of the puncture site after 2
minutes. Only 14 cases showed contrast medium extrava-
sation at 2 minutes, which was no longer present at the 5
minute control (Fig. 1).
No major complications were encountered. A minor
complication, a hematoma <3 cm, occurred in one (0.7%)
of 148 ExoSeal closure procedures despite technically suc-
cessful vascular closure. The patient who developed a he-
matoma was on continued dual antiplatelet therapy (ASS
and clopidogrel) and received intervention via a 6F access.
There were no clinically detectable pseudoaneurysms or
intravascular plug applications.Figure 1. Digital subtraction angiograms via a retrograde 18G/3.8F femo
after ExoSeal closure of an ipsilateral antegrade puncture. Angiography
antegrade access site after 2 minutes of manual compression (A), noPre- and intra-interventional anticoagulation therapy was
documented in all cases. In all cases heparin was adminis-
tered during intervention and was continued for 24 hours
post-interventionally. There were 40 patients (27.0%) who
were treated with a combination of ASS, clopidogrel, and
heparin. Sixty-seven patients (45.3%) received only ASS in
addition to heparin, while one patient (0.7%) was on clo-
pidogrel and heparin only. Four patients (2.7%) received 5e
10 mg abciximab during intervention in addition to heparin
and ASS. In the remaining 36 cases (24.3%) heparin alone
was administered. Sixteen patients were treated with
phenprocoumon, which was substituted with heparin in all
cases prior to intervention.
The patient in need of prolonged manual compression
after successful ExoSeal deployment was on heparin and
ASS only.
Statistical analysis of angiographically conﬁrmed time-to-
hemostasis
Logistic regression of the continuous variables showed pre-
interventional aPTT to be the only statistically signiﬁcant
predictor of the need for 5 minutes rather than 2 minutes
manual compression (p ¼ .01). The odds ratio for aPTT,
however, was only 1.038 (CI 1.009; 1.069). All other
continuous variables (patient age, INR, platelet count) were
excluded from the model. However, an elevated INR (>1.5)
showed an odds ratio of 2.455 (CI 0.270; 22.322) for the
probability of 5 minutes rather than only 2 minutes manual
compression.
Analysis for discrete variables yielded a statistically sig-
niﬁcant correlation between the need for 5 minutesral cannula placed in the right CFA 2 minutes (A) and 5 minutes (B)
shows residual contrast medium extravasation from the VCD-closed
longer present after an additional 3 minutes of compression (B).
Efﬁcacy and Time-To-Hemostasis 589compression and the application of ASS (p ¼ .01), clopi-
dogrel (p < .01), and abciximab (p < .001), as well as any
combination of these drugs. In fact, all patients (n ¼ 4)
receiving abciximab intra-interventionally showed residual
bleeding at 2 minutes, which was no longer present after 5
minutes.DISCUSSION
Antegrade femoral access is commonly used for percuta-
neous revascularization especially in patients with infrain-
guinal vascular disease. Whereas in retrograde femoral
punctures a lower puncture angle can be achieved, making
VCD use feasible, antegrade punctures of the common
femoral artery often require a steeper puncture angle and
are technically more challenging, especially in obese
patients.1
Several VCDs are available today, employing different
closure mechanisms. In general the safety and efﬁcacy of
these VCDs has been conﬁrmed for retrograde access in
several studies11e13 even in patients receiving anticoagulant
therapy14,15 or after repeated closures.8,16
Despite a steeper puncture angle, VCDs are also
increasingly used for the closure of antegrade femoral ac-
cess sites.4,5 Studies examining the safety and efﬁcacy of
antegrade vascular closure devices demonstrated effec-
tiveness in obtaining hemostasis. In a large, single-center
study of 1889 AngioSeal closures of antegrade femoral
punctures, Lupattelli et al. found an overall complication
rate of 2.5%.5 Spiliopoulos et al. reported a cumulative
minor complication rate of 5.3% after ante- and retrograde
femoral punctures and two major complications in 588
antegrade vascular closure procedures with the Starclose
device.4 For the Perclose device, Chiu et al. observed no
major complications and a minor complication rate of 33.7%
in 31 patients.17
Possible complications after vascular closure using VCDs
include hematoma or retroperitoneal hemorrhage requiring
transfusion and/or surgical intervention, infection/abscess,
arteriovenous ﬁstula, pseudoaneurysm, and ischemia.18,19
The ExoSeal VCD (Cordis Corporation, Miami Lakes, FL,
USA) is an alternative bioabsorbable device, which was
approved for retrograde common femoral artery closure in
2010.9 The dual visually guided device deployment mech-
anism, consisting of a bleed-back indicator and an intra-
vascular nitinol wire loop, is intended to minimize
manipulations that may cause discomfort at the access site
and enhance the safety of plug application.6
In a randomized comparison of the 6F ExoSeal VCD to
manual compression (ECLIPSE trial), Wong et al. showed
that ExoSeal use is associated with a signiﬁcant shortening
of time-to-hemostasis as well as time-to-ambulation in pa-
tients undergoing cardiac interventions.6
To date only two studies have published the efﬁcacy and
safety of vascular closure in antegrade femoral artery
puncture using the ExoSeal VCD. Maxien et al. reported
technically successful plug deployment in 98.3% of cases
(n ¼ 59) and observed one pseudoaneurysm, two minorhematomas and one minor re-bleeding. There was no sta-
tistically signiﬁcant correlation between complication rate
and BMI, patient age, coagulation parameters, or calciﬁca-
tion of the femoral artery.10
Schmelter et al. reported an equally high technical suc-
cess rate of 96% in 100 interventions with antegrade access.
Failure of plug deployment occurred in only 4%. Minor
complications were encountered in 7% of cases (four
pseudoaneurysms and three re-bleedings).9
Although these initial results of ExoSeal vascular closure
of antegrade puncture sites with high technical success and
low complication rates are promising, the number of re-
ported cases is still rather limited. Additionally, both studies
only evaluated the 6F ExoSeal VCD. Since then, the ExoSeal
has become available in sizes from 5F to 7F. Also, both
studies used clinically determined hemostasis as an end
point. However, it remains unknown whether persistent
slight hemorrhage after 2 minutes of manual compression
not immediately detectable clinically can lead to a higher
risk of complications like pseudoaneurysm formation.
The purpose of this study was therefore to present ex-
periences with the ExoSeal VCD for antegrade femoral ac-
cess closure, especially regarding device efﬁcacy and time
to angiographically conﬁrmed hemostasis. The overall re-
sults are in line with the ﬁndings reported in literature. A
high technical (98.0%) as well as procedural success rate
(97.3%) was found, while complications related to the
closure procedure generally were rare.
The results of direct determination of hemostasis by
angiography after ExoSeal closure were further evaluated.
One-hundred and thirty of 145 cases (89.6%) showed no
contrast extravasation 2 minutes after ExoSeal deployment.
Only 14 cases (9.7%) showed incomplete vascular closure at
this time and required 5 minutes of manual compression.
Statistical analysis of the ﬁrst closure procedures in each
patient (n¼ 119) suggests that the need for 5 minutemanual
compression, instead of only 2 minutes, is to be expected in
patients receiving ASS, clopidogrel, abciximab, or a combi-
nation of these drugs as well as in patients with a prolonged
aPTT pre-interventionally. However, it remains unclear
whether pre-interventional aPTT values, although reaching
statistical signiﬁcance, really have a clinically relevant impact
on the time-to-hemostasis as the odds ratio is near 1, and
intra- and post-interventional heparin application performed
in all cases would prolong the aPTT anyway. Although heparin
was continued post-interventionally, vascular closure was
successful in the majority of cases within 2 minutes. The INR
showed the highest odds ratio for the need for 5 minutes
compression but failed to reach statistical signiﬁcance. It is
also interesting to note that the only minor complication
occurred in a patient receiving dual antiplatelet therapy. It
may be advisable, therefore, to prolong manual compression
after antegrade ExoSeal closure to 5 minutes in cases of an-
tiplatelet (especially dual antiplatelet) therapy. As all patients
who received abciximab during intervention showed
extravasation after 2 minutes, the authors advocate pro-
longing manual compression to at least 5 minutes if abcix-
imab is administered.
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additional retrograde access which necessitated further
manual compression for 5 minutes after control angiog-
raphy, preclude direct comparison of complication rates
with other studies. Nevertheless, only one minor compli-
cation (hematoma <3 cm) and no pseudoaneurysms were
observed in the group undergoing angiographic control.
It is noteworthy that in the three cases of technical
failure no major or minor complication occurred. This may
be because, in contrast to some other vascular closure
devices, especially those with an intravascular anchor, there
is always a so-called “safe exit strategy” by just pulling the
ExoSeal out of the vessel and performing manual
compression. If there is a problem during device posi-
tioning, the operator can switch to manual compression at
all times until deﬁnitive plug deployment.
A further advantage of the ExoSeal VCD is that the plug
dissolves over time without leaving a permanent implant.7
In all cases of repeated vascular closure, no hemostatic,
technical, or interventional difﬁculties were experienced,
even though the time between two closures was shorter
than the time the plug takes to dissolve completely
(approximately 3 months7) in most cases. Therefore,
repeated closures with an ExoSeal VCD of an antegrade
puncture site seems to be feasible. This has already been
shown for retrograde arterial access closures.8
There are some limitations to the present study. Available
data were analyzed retrospectively. A randomized compar-
ative analysis of all three ExoSeal sizes to manual
compression or other vascular closure devices would be
desirable. However, the results of angiographic control of
ExoSeal closure are reported, which to the authors’
knowledge, have not been investigated before. One has to
bear in mind though that in patients with an additional
ipsilateral 18G/3.8F retrograde access, it is difﬁcult or even
impossible to differentiate the antegrade or retrograde
puncture as a possible cause of bleeding after both vascular
accesses have been removed. However, as there was only
one case of minor hematoma in this study group with both
a retrograde and antegrade access, this was not a relevant
problem. The additional 5 minutes of manual compression
of the retrograde access site make direct comparison of
these data with other studies difﬁcult. The low rate of
complications, however, shows that secondary bleeding
after primary hemostasis is a rare event.
Furthermore, it remains unknown whether a slight
contrast medium extravasation after 2 minutes detectable
on angiography but not clinically would really lead to a
higher complication rate or whether it may be self-limiting
within a few minutes. This question cannot be answered in
this group because additional manual compression was
applied in each case of remaining extravasation after 2
minutes until complete hemostasis was achieved.
One also has to bear in mind that there were only 14
cases needing 5 minutes rather than only 2 minutes MC,
and only one case needing >5 minutes MC, limiting the
conclusiveness of the statistical analysis. As procedural
success is very high, with 2 minutes compression beingsufﬁcient in the vast majority of cases, a study with a much
larger patient group would be necessary to validate the
ﬁndings of this analysis.
In summary, the results of this study suggest that the
ExoSeal vascular closure device is safe and effective in the
closure of antegrade femoral access for percutaneous
vascular interventions. In patients receiving antiplatelet
therapy and especially after the intra-interventional appli-
cation of abciximab, the authors advocate prolonging
manual compression from 2 minutes to 5 minutes to avoid
residual bleeding after antegrade access closure.
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